

## **Prospects for adult stem cells in the treatment of liver diseases**

Running title: adult stem cells in liver disease

Sharmila Fagoonee<sup>1\*</sup>, Elvira Smeralda Famulari<sup>2</sup>, Lorenzo Silengo<sup>3</sup>, Giovanni Camussi<sup>4</sup> and Fiorella Altruda<sup>5\*</sup>

<sup>1</sup>Institute of Biostructure and Bioimaging, CNR, Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, 10126, Turin, Italy; sharmila.fagoonee@unito.it

<sup>2</sup>Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, 10126, Turin, Italy ; elvsmefamulari@gmail.com

<sup>3</sup>Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, 10126, Turin, Italy; lorenzo.silengo@unito.it

<sup>4</sup>Department of Medical Sciences, University of Torino, 10126 Torino, Italy, giovanni.camussi@unito.it

<sup>5</sup>Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, 10126, Turin, Italy; fiorella.altruda@unito.it

\*Corresponding authors:

Sharmila Fagoonee (sharmila.fagoonee@unito.it) and Fiorella Altruda (fiorella.altruda@unito.it)

Via Nizza 52,

10126 Turin,

Italy

## Abbreviations

OSM: oncostatin M, HSC: hematopoietic stem cells, HLSC: human liver stem cells, GPSC: germline cell-derived pluripotent stem cells, ES: embryonic stem, iPS: induced pluripotent stem, ASC: adipose-derived stem cells, FGF: fibroblast growth factor, BMP: bone morphogenetic protein, AFP: alfa-fetoprotein, HNF: hepatocyte nuclear factor, MSC: mesenchymal stem cells, Ugt1A1: UDP- glucuronosyltransferase A1, E: embryonic day

## Abstract

Hepatocytes constitute the main bulk of the liver, and perform several essential functions. After injury, the hepatocytes have a remarkable capacity to regenerate and restore functionality.

However, in some cases, the endogenous hepatocytes cannot replicate or restore the function, and liver transplantation, which is not exempt of complications, is required. Stem cells offer in theory the possibility of generating unlimited supply of hepatocytes *in vitro* due to their capacity to self-renew and differentiate when given the right cues. Stem cells isolated from an array of tissues have been investigated for their capacity to differentiate into hepatocyte-like cell *in vitro*, and employed in rescue experiments *in vivo*. Adult stem cells have gained in attractiveness over embryonic stem cells for liver cell therapy due to their origin, multipotentiality, and the possibility of autologous transplantation. This review deals with the promise and limitations of adult stem cells in clinically restoring liver functionality.

## **Introduction**

The liver is one of the largest organs and central metabolic hub of the human body. The liver interacts with all body systems and receives blood through two distinct routes: the hepatic artery which brings blood from the systemic circulation, the portal vein which delivers blood drained from the spleen and digestive tract. Hepatocytes constitute the main bulk of the liver, and perform a wide range of functions such as protein synthesis (example, acute phase proteins synthesis), detoxification, carbohydrate and lipid metabolism, and bile production [1,2]. Another essential function is filtration due to the presence of small fenestrations that allow free diffusion of many substances between blood and hepatocyte surface [3]. The liver is prone to bacterial and viral infection, and shows tropism for circulating cancer cells, like for instance, colorectal cancer cells [4-6]. The liver is thus under continuous assault from various internal and external factors, which may alter organ function. The hepatocytes have a remarkable capacity to regenerate after injury and restore functionality. However, when the inherent regenerative capacity of hepatocytes is impaired, liver transplantation becomes the only efficient treatment. This procedure, however, is highly invasive, is limited by the scarcity of donors, and is not exempt of complications. Following transplantation, the outcome of the patient may change on the basis of hypotension, hypoxia, ischaemia and hepatotoxic drugs, surgical-related aspects (intra- or postoperative hemorrhage, vascular or biliary complications, infections), problems posed by prolonged use of immunosuppressive drugs (infections, toxicity and possible neoplastic risks) or rejection [7].

Transplantation of hepatocytes is an attractive alternative. The first hepatocyte infusion was carried out as early as 1976 in the Gunn rat model which closely mimics the pathological manifestations in Crigler-Najjar syndrome type I patients [8,9]. Following modeling of hepatocyte transplantation in several animal models, the first preclinical study was performed in 1992 in non-human primates to evaluate the safety and efficacy of infusing adult hepatocytes in the portal vein [10,11]. Thereafter, human clinical hepatocyte transplant has been carried out in several liver

diseases, mostly as therapy for innate metabolic failures or post-resectional liver failure (as a definitive treatment) in an effort to restore functionality [8,12]. More than 30 human cases receiving hepatocyte transplantation for metabolic diseases have been reported hitherto [13]. Human hepatocyte treatment for fulminant or chronic liver failure with acute decompensation (as a bridge to liver transplantation) has extended the life expectancy of patients for years [8,9,14]. Hepatocytes have been isolated from donated human livers considered unsuitable for organ transplantation. Not always good quality hepatocytes are obtained from these livers (due to long cold ischemic times or presence of steatosis) and, when cultured *in vitro* in different conditions (oxygenated co-cultures or microfabricated culture chips, for instance), these cells lose their metabolic functions after some time [9,15,16]. Recently, a long-term culture and expansion method of primary human hepatocytes has been described [17]. Primary human hepatocytes were transduced with human papilloma virus genes E6 and E7 which induce the expression of the oncostatin M (OSM) receptor, gp130. Thus, treatment of the cells with OSM promoted proliferation, and hepatocytes could be expanded for up to 40 population doublings, producing bulk quantity of cells *in vitro*. Removal of OSM enhanced the differentiation of the hepatocytes into cells with transcriptional, metabolic and toxicity profiles resembling those of primary hepatocytes [17]. This is a major leap forward in the quest of finding conditions to expand primary human hepatocytes which maintain the capacity to undergo maturation *in vitro*. At the moment, this is the cell therapy with the best evidence of engraftment and generation of functional liver parenchyma compared to hepatocytes derived from other sources (described below) [13]. Still, much work needs to be done to obtain cell therapy-quality hepatocytes, produced under Good Manufacturing Practice (GMP) conditions, for liver transplant in humans. There are, however, problems with long-term survival of hepatocytes. And importantly, despite the fact that no HLA matching is required for hepatocyte transplant in the liver, hence allowing the use of ample donor-derived stem cells for cell therapy, immunosuppression is still required [9,18]. Thus, the potential advantages of using

hepatocyte infusions must be carefully evaluated against any possible side effects resulting from the use of immunosuppressive drugs, sepsis, embolization of cells into the lungs, for example [19].

Another promising advance in the field of liver cell therapy has been made with the discovery of stem cells and their potentiality. Stem cells offer, in theory, the possibility of generating unlimited supply of hepatocytes due to their capacity to self-renew and differentiate when given the right cues. The perfect stem cell-derived hepatocyte would be one which changes the trajectory of the liver disease and definitively restores functionality. Hepatocyte-like cells fulfilling, at least partially, these criteria have been obtained from both pluripotent embryonic stem (ES) cells and adult stem cells. The clinical application of ES cells, however, has been hampered by ethical concerns raised over the embryo use, and the problems of immune incompatibility between donors and recipients. Another major concern is the risk of tumor formation (teratomas) arising from ES cell injection. It has been shown that teratomas form *in vivo* not only from undifferentiated human ES cells, but also from human ES cells differentiated *in vitro* for long periods of time [20]. Adult stem cells, on the other hand, despite their lower engraftment and repopulation efficiency compared to mature hepatocytes, have gained in attractiveness for liver cell therapy due to their multipotentiality, ability to differentiate into hepatocyte-like cells and, especially, for their use in an autologous way. This review deals with the promise and limitations of adult stem cells in restoring liver functionality.

## **Methodology**

A MEDLINE search of all studies published in English (last performed on 15th June 2016) was conducted. Articles on the use of hepatocytes and stem cell-derived hepatocytes liver diseases were identified and selected using the terms "Liver transplantation AND hepatocytes AND stem cells".

## **Stem cells differentiated into hepatocytes *in vitro***

Hepatocytes are the main cell type in the liver accounting for 70% of the mass of the adult organ. Hepatocytes, along with biliary epithelial cells or cholangiocytes, are derived from the embryonic endoderm that emerges at embryonic day (E) 7.5 in mouse, and in the third week of human gestation [21]. The activity of two important cytokines, fibroblast growth factor (FGF) secreted by the developing heart, and bone morphogenetic protein (BMP) arriving from the septum transversum mesenchyme orchestrates the endoderm cells to adopt a hepatic fate [22]. The liver-committed foregut endoderm cells then express transcription factors Hex and HNF4 $\alpha$ , and the liver-specific genes  $\alpha$ -fetoprotein (AFP), and albumin. These cells migrate as cords into the surrounding septum transversum mesenchyme, and become the common progenitor cells (hepatoblasts) which give rise to both hepatocytes and cholangiocytes during liver development [22]. Factors employed for directing hepatocyte specification and maturation to induce hepatic differentiation of stem cells and *in vitro* differentiation protocols have emerged from the knowledge acquired on fetal liver development *in vivo*. Several types of adult stem cells have been differentiated *in vitro* into functional hepatocytes, and employed in preclinical studies as well as in clinical settings (Table 1). Some examples are described below.

### **Hematopoietic stem cells**

Hematopoietic stem cells (HSCs) and hepatocytes are entwined since early embryonic development. The mid-gestation fetal liver is the major transitional site for mammalian hematopoiesis [21]. HSCs secrete several cytokines and growth factors that promote hepatocyte maturation. HSCs then migrate to the fetal bone-marrow, and switch from liver to bone marrow hematopoiesis occurs at around E16 in mice and after 70 days' gestation in humans [23,24]. The finding that the multipotent HSCs can participate in liver repair in adult life is therefore not such a surprise. HSCs are the most studied adult stem cells and can be isolated through the expression of c-Kit<sup>+</sup>Sca-1<sup>+</sup>Lineage<sup>-</sup> in rodents and CD34 or CD133 in humans [25]. It has been shown that adult bone marrow stem cells such as HSCs and mesenchymal stem cells (MSCs, discussed below) are a

potential source of hepatic progenitor cells, termed oval cells (described below), in rodents and are capable of restoring liver functions, for example in the lethally irradiated tyrosinemic FAH<sup>-/-</sup> mice, or following carbon tetrachloride (CCl<sub>4</sub>) induced liver fibrosis [23,26]. There are also several human clinical studies reporting the improvement in liver function, for example, following HSC transplant in liver diseases or in the setting of patients needing liver regeneration before hepatic resection of metastases [27-29]. The small number of cases reported, lack of defined primary endpoint as well as absence of controls render these results difficult to interpret and evaluate [27]. Furst *et al.* elegantly showed how the infusion of autologous CD133<sup>+</sup> cells into the non-occluded portal vein following portal venous embolization with chemotherapy caused an extensive increase in the residual liver lobe size [29]. This increase in liver volume was significantly higher in the CD133-treated group compared to controls thus permitting earlier surgery for resection of hepatic metastases. In a recent study, Schmelzle *et al.* showed that a subset of murine and human HSCs express high levels of CD39 which directs the chemotaxis and recruitment of these CD39<sup>high</sup> HSCs from bone marrow to liver [30]. The CD39-positive HSCs significantly increased in the bone marrow after 70% hepatectomy in mice and promoted liver regeneration. In the clinical setting, mobilization of human HSCs was observed 2 days after liver hepatectomy and was associated with the extent of liver resection as well as growth and functionality after hepatic resection. However, the mechanisms by which extrahepatic stem and progenitor cells participate in liver regeneration still need elucidation.

### **Mesenchymal stem cells**

MSCs, due to their multipotency, immunoregulatory/ immunosuppressive and migratory properties, and *quasi*-unlimited availability, have extensively been investigated as potential therapeutic options for the treatment of several degenerative diseases [31]. MSCs are derived from adult tissues and are considered safer in terms of tumorigenicity with respect to pluripotent stem cells (described below) [32]. These MSCs have been obtained from several tissues including bone

marrow, cord blood, amniotic fluid, adipose tissue, and most recently, from the liver [33-38]. In particular, there are several advantages in using adipose tissue-derived MSCs, or ASCs, for hepatocyte derivation: their abundance and easy accessibility from minimally invasive procedures like liposuction surgery, and their higher yield of stem cells upon isolation with respect to other tissues [39,40]. This is a crucial point as at least one million/kg body weight of MSCs are required for transplantation each time [41]. Meticulously performed studies have provided the evidence that cells with functional characteristics of hepatocytes can be obtained from multiple tissue-derived MSCs *in vitro*. For example, when MSCs were treated with HGF, nicotinamide, and dexamethasone, these cells exhibited features that closely resembled human adult hepatocytes, and expressed hepatic markers such as albumin and AFP [42]. MSCs act at several levels in tissue restoration after injury. These cells provide immunomodulatory, anti-inflammatory, antifibrotic, anti-apoptotic and pro-proliferative features [43,44]. Several clinical studies using autologous MSCs, sometimes in the presence of cell-maintained biomaterials, have been performed in various fields (Table 1). For instance, Koh *et al.* have shown that the injection of ASCs and platelet-rich plasma into 18 patients with osteoarthritis or degenerative cartilage effectively reduced pain and improved knee function in patients undergoing treatment for knee osteoarthritis [45]. However, it is their *in vivo* propensity to stimulate resident cells and matrix remodeling, through expression of trophic factors (growth factors and anti-fibrotic molecules such as HGF and cytokines) to promote the differentiation of native progenitor cells as well as the recovery of injured cells, that makes MSCs optimal candidates for liver repair [28,41,46]. For example, allogenic bone marrow-derived MSCs transplantation has been performed in patients with primary biliary cirrhosis, and the outcome was the improvement in liver function [47]. Other clinical trials investigating the effect of bone marrow-derived stem cells in patients with liver disease have been performed and have established the safety and feasibility of stem cell therapy in patients with liver diseases (extensively reviewed in [44]). On the other hand, some studies have pointed out to the possibility that MSCs, for instance, those derived from bone marrow, may contribute to the hepatic stellate cell populations



and myofibroblast pool, and thus, promote the fibrotic process within the liver [48,49]. Excessive extracellular matrix deposition may occur overcoming the MSC-induced cytoprotective effect taking place during the initial repair process [41]. Thus, more clinical studies are needed to ensure that MSCs, especially the ones derived from the bone-marrow, can be safely employed to generate new hepatocytes to replace damaged ones without leading to fibrosis.

### **Adult pluripotent stem cells**

The pluripotent stem cells *par excellence* are the ES cells but due to ethical and immunological concerns, their use in the clinic has been forbidden in most countries. The scientific breakthrough of the group of Yamanaka has offered the possibility of obtaining adult pluripotent alternatives [50]. Induced pluripotent stem (iPS) cell, generated by reprogramming of somatic cells, are very attractive for regenerative therapy for the following reasons. These adult cells can be expanded for long period in culture without karyotype change; they can be frozen and thawed without loss in viability as may happen for other types of adult stem cells; and most importantly, they can give rise to derivatives of the three germ layers upon differentiation induction without the concern for immune rejection for potential patient-tailored therapy [50,51]. Functional hepatocytes have been derived *in vitro* from human iPS cells, both of human and mouse origin, by several groups [52-54]. HNF4, albumin, cytokeratin 18 (CK-18), glucose 6-phosphate (G-6P), cytochrome P450 3A4 (CYP3A4), and cytochrome P450 7A1 (CYP7A1) were expressed by the iPS cell-derived hepatocytes [54]. Moreover, in functional assays, these cells showed accumulation of glycogen, and demonstrated uptake and excretion of indocyanine green, as well as secretion of albumin into the medium [53]. These iPS cell-derived hepatocytes rescued lethal fulminant hepatic failure in mice [53,54]. Thus, patient-specific iPS cell-derived hepatocytes can be obtained for promoting liver regeneration *in vivo* or for therapeutic compound testing or studying disease mechanisms *in vitro*. However, one of the most important concerns about use of iPS cells compared to that of adult stem cells is the possibility of developing some tumoral tissue [55]. Thus,

it is important to ensure that full differentiation of ES-like cells has occurred before proceeding to transplantation in humans. Efforts are now being made to improve the mechanism and method for generating tumor-free iPS cells, like employing the suicide-gene strategy or using regulatory miRNAs in iPS cell-based therapy [55,56]. Despite all hurdles and controversies, clinical trials in treatment of spinal cord injury, macular degeneration of retina, type 1 diabetes and heart failure are under way [57].

Pluripotent stem cells derived from spermatogonial stem cells, termed herein as germline cell-derived pluripotent stem cells (GPSCs), are also adult stem cells with the major features of ES cells. The difference with iPS cells is that mouse GPSCs are obtained spontaneously from long-term cultures of spermatogonial stem cells and do not necessitate the genetic reprogramming by forcing gene expression for their derivation. GPSCs are thus of particular interest for tissue regeneration [58]. The first clue that GPSCs can be directed to differentiate into hepatocyte-like cells came from the study of Guan *et al.* [59]. GPSCs were cultured as "hanging drops" for five days, and plated thereafter. Hepatocyte-like cells were observed in the embryoid bodies, and gene expression analyses revealed that the early (AFP) and the late (CK-18) markers of hepatocyte differentiation were expressed. Successively, GPSCs were induced, using two different hepatic differentiation approaches, to differentiate in hepatocytes *in vitro* and were compared to other pluripotent stem cells [60]. GPSC-derived hepatocytes showed prominent expression of AFP, albumin, CK-18, and *c/ebp- $\alpha$*  and acquired a polygonal-shaped hepatic morphology. These cells also secreted albumin in culture supernatant. We confirmed these results and further showed that GPSC-derived hepatocytes were metabolically active as shown by albumin and haptoglobin secretion in the culture supernatant, urea synthesis, glycogen storage, and indocyanine green uptake [51]. Infection of GPSC-derived embryoid bodies with lentivirus expressing GFP under hepatocyte-specific enhanced transthyretin promoter revealed that 82.68% of cells were hepatocytes in long-term culture (on Day 35 of differentiation) [51,61]. An OP9 co-culture system was also shown to efficiently generate

functional and mature hepatocytes cells from GPSCs [62]. Recently, our group demonstrated that the hepatoblast marker, Liv2, -sorted GPSC-derived hepatocytes were functional *in vitro*, and could engraft and colonize Hfe-null mice livers following monocrotaline treatment and partial hepatectomy [63]. These studies showed that GPSC-derived hepatocytes could undergo long lasting engraftment in the mouse liver and are promising for liver regeneration. The starting cell type, spermatogonial stem cells, also show multipotent characteristics when given the right differentiation cues. To this regard, it was demonstrated that both mouse spermatogonial stem cells can directly transdifferentiate *in vitro* into cells with morphological, phenotypic and functional attributes of mature hepatocyte-like cells [64]. More recently, mature and functional hepatocytes have been also obtained by direct differentiation from freshly isolated human spermatogonial stem cells [65]. Thus, it may be possible to rapidly and directly differentiate adult spermatogonial stem cells into mature and functional hepatocyte-like cells, without waiting for the pluripotency acquisition process. The field is now open to finding the right culture conditions for the long-term culture of human spermatogonial stem cells (to derive human GPSCs) and to assess the clinical potentiality of both spermatogonial stem cells and GPSCs.

### **Resident stem cells**

Mature hepatocytes are usually quiescent and show minimal turnover [66]. However, following injury induced by partial hepatectomy or chemical insult, hepatocytes exit the G<sub>0</sub> phase and undergo cell proliferation to compensate for cell loss [42]. Resident stem cells are also thought to be involved in the liver regeneration process. Oval cells, defined as a population of small proliferating cells with oval-shaped nuclei in rodents, surge within the liver following injury [67]. Oval cells are bipotent cells that are capable of generating both hepatocytes and bile duct cells [68]. Some studies have reported the identification of oval cell equivalent in human in the so-called "ductular reaction" [68]. Bipotential progenitor epithelial cells resembling rodent oval cells, morphologically and immunohistochemically, have been traced in the regenerating areas in patients

with chronic liver injury in subacute hepatic failure [69,70]. Recently, Huch *et al.* have reported the long-term culture of adult bile duct-derived bipotent stem cells isolated from human liver biopsies [71]. Interestingly, these cells could be induced to differentiate into functional hepatocyte cells in organoids *in vitro* and upon transplantation *in vivo* in mice. These data suggest that the human counterpart of oval cells exists and may participate in liver regeneration. Whether these cells originate in the liver itself or in extrahepatic sites such as the bone-marrow still remains a matter of doubt [72]. Lineage tracing experiments may help in this direction. Some studies indicate that the activation of progenitor cells (oval cells in rodents) may lead to the histogenesis of hepatocellular carcinoma or in the development of liver fibrosis [73,74]. More studies are thus needed to clarify the mechanisms that in one instance leads to the hepatic differentiation of oval cells in normal liver, and on the other hand, promotes their carcinogenicity under pathological conditions.

A population of human liver stem cells (HLSCs) has also been isolated from surgical specimens of patients undergoing hepatectomies or from cryopreserved normal hepatocytes [68,75]. These cells express mesenchymal stem cell markers, and can be induced to differentiate into mature hepatocytes when cultured in the presence of HGF and FGF4 in rotary cell culture system *in vitro*. *In vivo*, HLSCs contributed to liver regeneration when injected in SCID mice with N-acetyl-p-aminophen-induced acute liver injury and improved survival of mice with fulminant liver failure [68,75]. Thus, these preclinical studies are a prelude to assessing the clinical use of HLSCs. Regarding the use of human adult liver stem cells in treating inborn errors of liver metabolism, patients have been included in phase I/II studies, including Crigler-Najjar and urea cycle disorders[76].

### ***In vitro* systems for obtaining functional hepatocytes from stem cells**

Stem cells-derived hepatocytes cultured on different extracellular matrix components in monolayers do not undergo full maturation *in vitro*. Using 3D bioreactors and rotating microgravity conditions, some studies have demonstrated that hepatocyte viability and function can be improved

and maintained for several weeks [68,77]. However, there are contrasting data regarding the effect of microgravity on differentiation. Lately, it has been reported that microgravity reduces the differentiation and regenerative properties of stem cells [78]. Thus, other settings have to be devised to promote maturation of stem cells into functional hepatocytes *in vitro*. It is known that hepatocytes need heterotrophic cell interactions with non-parenchymal cells which regulate differentiation and proliferation in a 3D microenvironment *in vivo* [79]. Importantly, stem cell-derived hepatocytes need the optimal microenvironment when transplanted in the case of end-stage chronic liver disease, for instance, in which the liver architecture is extensively destroyed and the liver parenchyma is replaced by fibrosis with reduced blood supply. Generation of acellular liver scaffolds from rat or human liver for repopulating these with stem-cell derived hepatocytes is a great step forward in mimicking the *in vivo* system (Figure 1). For instance, rat liver scaffolds were recellularized with HLSCs and maintained for 21 days in different culture conditions to evaluate hepatocyte differentiation [80]. The rat extracellular matrix enhanced HLSC differentiation into functional and metabolically hepatocytes, and promoted the formation of both epithelial-like and endothelial-like cells [80]. Human segmental lobes or whole liver have been also decellularized and characterized [81]. The scaffold was repopulated with different human hepatic cell lines for up to 21 days, and allowed efficient engraftment, homing to correct location, and proliferation of these cells. The human liver scaffold also showed biocompatibility when xenotransplanted into immunocompetent mice [81]. This is a major progress in devising bioartificial livers for repopulation with stem cell-derived hepatocytes for the treatment of liver diseases.

### **Modeling human diseases for assessing stem cell-derived hepatocyte function**

Stem cell-derived hepatocytes have been transplanted mainly in rodents to test their functionality *in vivo*. To counteract the rejection of human cells by the rodent immune system, immunodeficient mice have been employed for the transplantation of stem cell-derived hepatocytes. But often the human cells do not proliferate in normal livers. Thus, several animal models, in which

proliferation of endogenous hepatocytes is severely compromised, either by genetic causes or by accumulation of toxic products, have been generated. For instance, fumarylacetoacetate hydrolase (FAH)-deficient mice and urokinase (alb-PA) transgenic mice with liver regeneration defects, have been transferred into an immuno-compromised background to receive human cells [79].

Transplanted stem cell-derived hepatocytes thus have selective growth advantage over endogenous hepatocytes, and homing, engraftment, and proliferation, as well as functionality can be assessed.

Mice with inherited liver metabolic diseases caused by genetic mutations in key proteins, for example, Crigler-Najjar in which the Ugt1A1 gene is mutated, have been generated, and crossing these mice with immuno-compromised mice will help in assessing whether human stem cell-derived hepatocytes can rescue the phenotype [82]. These mice have normal liver, and a way to make exogenous hepatocytes home and proliferate has to be found. The engrafted cells will thus restore the activity of the enzyme UDP- glucuronosyltransferase A1. Thus, apart from cell therapy, stem cells also serve as a platform for gene therapy. In humans, such an approach can be envisaged in personalized gene/stem cell therapy combination following genome editing.

Several routes of cell delivery to the liver have been exploited. The most convenient mode of stem cell-derived hepatocyte transplantation is the intravenous route [83]. This delivery route takes the injected cells to the lungs and successively to the liver. Liver injury and release of cell attracting chemokines are required for homing of injected cells. The spleen is also a good site for hepatocyte injection. The hepatocytes infused into the spleen undergo blood flow-mediated translocation to the hepatic sinusoids [84]. However, a large number of cells remain trapped in the spleen. Other routes of infusion include hepatic artery and portal vein [85]. Intraparenchymal hepatocyte transplantation is another way of delivering cells to the liver [63]. Directed injection results in grafted cells that remain localized to the liver. Most recently, hepatocyte sheets were attached onto the surface of mice livers following injury and showed high potential for cell

engraftment of this sheet transplantation procedure [86]. Thus, the therapeutic values of stem cell-derived hepatocytes can be assessed *in vivo* using these different routes of cell delivery to liver.

### **Stem cell secretome in mediating beneficial effect on liver**

Liver regeneration occurs, not only through transplanted stem cell proliferation and maturation, but also by the paracrine factors released by these cells. It was shown that microvesicles, which are shedded vesicles ranging from 100nm to 1µm in size, can horizontally transfer genetic information to target cells [87]. *In vivo* administration of microvesicles derived from HLSCs promoted *in vivo* liver regeneration in 70% hepatectomised rats [88]. The HLSC-derived microvesicles contain ribonucleoproteins involved in RNA biogenesis, microRNAs associated with multiple cell functions like transcription, translation and proliferation, as well as proteins [89]. Microvesicles also have other interesting properties. Recently, Fonsato *et al.*, demonstrated that HLSC-derived microvesicles could block the proliferation and survival of hepatocellular carcinoma cells *in vitro*, and induced the regression of ectopic tumors developed in SCID mice [90]. MicroRNAs contained in the microvesicles mediated the anti-tumor activity. Interestingly, cells can be genetically engineered to produce microvesicles carrying suicide mRNAs/proteins to target tumor cells [91]. Mesenchymal stem cell-derived extracellular vesicles have also been beneficial in several acute and chronic liver disease models (reviewed in [92]). Recently, comparison of adult-derived human liver stem/progenitor cells (parenchymal) to hepatic stellate cells (non-parenchymal) revealed that the former secreted cytokines with therapeutic and immuno-modulatory properties with respect to hepatic stellate cells [46]. Thus, stem cells can be beneficial for liver therapy not only physically, but also by effectively delivering therapeutic mRNA/proteins for repair and tumor regression.

### **The still unmet challenges**

Several aspects of liver cell/gene therapy need further investigations before stem cells can be efficiently used in the clinic. In animal models employed hitherto, it has been possible to block

endogenous hepatocyte proliferation with alkaloids such as monocrotaline, hence favoring the replication of transplanted stem cells. In patients, however, a similar treatment cannot be applied. Thus, strategies to harness growth advantages of stem cells in human liver which present a normal phenotype, like in the case of Crigler-Najjar syndrome, should be elaborated. Future studies will determine whether co-transplantation of stem-cell derived hepatoblasts and "helper" liver-derived stromal cells will engraft and gradually replace morphologically (but not metabolically) normal hepatocytes as was described in the rat [13]. However, fibrosis, which may occur as a side effect of such a procedure, should be taken into consideration. Standardization and protocols should be implemented for isolation, purification, culture conditions and passages, expansion, and hepatocyte-specific induction following Good Manufacturing Practice guidelines [93]. To which extent a stem cell should be differentiated *in vitro* to be considered fit for transplantation should be also standardized. To this regard, expression of markers of hepatocyte differentiation should be closely followed to assess the differentiation stage before cell injection. And whether hepatoblasts or fully mature hepatocytes should be injected in the diseased liver also remains a matter of concern, especially because some studies have shown that fetal hepatocytes proliferate, engraft and repopulate livers better than more mature ones [94]. But then, when considering iPS-derived hepatocytes, for example, the more differentiated the better it is? All these questions are still without an answer. The risk assessments for the liver transplantation of each stem cell type should be evaluated in clinical studies due to the fact that the isolation procedures as well as culture conditions can alter clinical efficacy and safety.

Future research should also address the issue of time. The time taken to isolate, expand and prime patient-specific stem cells into hepatocytes should be greatly reduced, so that autologous transplantation can be carried out in a timely manner, especially for acute hepatic diseases. Whether autologous stem cell therapy will be applicable in case of human fulminant hepatic failure, in which rapid deterioration of the liver function occurs and immediate cure is required, remains a matter of



concern. Moreover, following transplantation, stem cell-derived hepatocytes encounter a complex and hostile environment in which local hypoxia, oxidative stress, and inflammation may induce cell death. Insufficient retention and survival of transplanted cells may drastically dampen their therapeutic effects. Thus, tissue engineering approaches (for example, tissue scaffolds) should be ameliorated, and the addition of adjuncts that increase the proliferation as well as differentiation of stem cells into not only hepatocytes, but also all the other cell types making up the liver such as sinusoid endothelial, Kupffer, stellate and biliary epithelial cells may help in this regard [40].

An important issue is the fate of the stem cell-derived hepatocytes once injected in the patients through different routes mentioned above. Do these cells migrate to the liver? Do they complete their differentiation or are eliminated after some permanence in the liver? Another still unanswered question is whether the bone marrow-injected stem cells infused into patients really differentiate into hepatocytes or fuse with pre-existing ones or remain unaltered and release paracrine factors such as growth factors, angiogenic factors, cytokines, microvesicles, among others, to enhance regeneration through the stimulation of resident parenchymal or progenitor cells. Moreover, while in preclinical models, it is possible to assess engraftment and colonization efficiency of transplanted cells by an array of cell tracking methods (fluorescent dyes, magnetic resonance imaging) available, it is often technically difficult to perform on the long-term in patients in the clinical setting. Couto *et al.* employed  $^{99m}\text{Tc-SnCl}_2$  specific for mononuclear cell labeling to gain knowledge on the biodistribution of peripherally-infused bone marrow mononuclear cells in cirrhotic patients [95]. Interestingly, the authors found that approximately 41% and 32% of the radioactivity, as revealed by whole body scintigraphy, was retained in the liver 3 and 24 h after injection, respectively. Cell tracking, in this case, helped in assessing the correct homing of the injected cells to the liver at early time points, but could not be used to assess the colonization efficiency months after cell injection. Only one infusion of cells is temporarily beneficial. Repeated injections are probably needed to permanently reverse the damage [95]. For instance, in a Phase II

study, patients with complex perianal fistulas were randomly assigned to intralesional treatment with fibrin glue or fibrin glue plus 20 million ASCs [96]. In the absence of healing, a second dose of fibrin glue and 40 million ASCs were administered to the patients, and this enhanced the probability of healing by more than four times in patients treated with ASCs plus fibrin glue than in patients treated with fibrin glue alone. A retrospective study performed on these patients showed the long-term safety of the treatment despite the fact that a low proportion of patients treated with stem cells with closure after the procedure had no recurrence after 3 years' follow up [97].

Several studies have shown the long-term rescue of liver diseases using primary hepatocyte transplantation [98,99]. That hepatocytes derived from all different adult stem cell types can efficiently engraft and restore liver function on the long-term still need detailed investigations [100]. Large randomized controlled clinical trials are required to get robust data on the benefit of adult stem cell transplantation in liver diseases and to tailor treatment to individual patients, thus reducing the risk of rejection [44]. Despite the fact that several studies using stem cells in the treatment of liver diseases have shown beneficial effects, the underlying mechanisms responsible for their therapeutic effects are still unknown. Moreover, the percentage of liver colonization is still very low in spite of arduous efforts to ameliorate cell engraftment. The best application route should be investigated for each adult stem cell type used in order to maximize engraftment. Transplanted stem cell-derived hepatocytes secrete factors that contribute to liver repair and regeneration, but what recovery processes are regulated by these soluble factors remain undetermined.

The bone marrow contributes functionally and significantly to liver fibrosis and is a potential therapeutic target in liver fibrosis [49]. However, there are controversies on this subject that still have to be dealt with. MSCs from bone marrow have also been reported to inhibit hepatic stellate cell activation or induce their apoptosis, particularly *via* paracrine mechanisms, and therefore, may be considered in the treatment of liver fibrosis [101]. Clinical studies on bone

marrow cell therapy for liver regeneration and repair should thus proceed cautiously while evaluating the risk of hepatic fibrosis development [102].

In case of liver cancer, stem cells may create an immunosuppressive environment by providing anti-aging, anti-oxidative effects, for example by reducing reactive oxygen species, and hence favor the escape of tumor cells and promote metastasis formation [103]. When performing therapy with stem cells, one should not lose sight of the possible implication of these cells in carcinogenesis (reviewed in [104]). In the liver, several cell types (hepatocytes, cholangiocytes, progenitor cells) live long enough to be the cell of origin of cancer [105]. In fact, the presence of CK7 and CK19-positive progenitor cells has been found in a substantial number of hepatocellular carcinoma cases [106]. Hepatocellular carcinoma may also originate from the transdifferentiation of bone marrow cells as also happens in other sites of the digestive tract [107,108]. These results suggest that there may be more than one type of carcinogen target cell in the liver.

## **Conclusions**

Adult stem cells have been isolated from diverse body tissues and their capacity to differentiate into hepatocyte-like cells *in vitro* and restore liver functions *in vivo* has been investigated extensively, as depicted in Figure 2. Now, the major goal is to translate the knowledge gained on animal models into clinic which is awaiting the "perfect" stem cell(s) to reduce death caused by acute and chronic liver diseases, often not curable by pharmacological approach. Hepatocyte infusion and stem cell-derived hepatocyte transplantation performed in humans are till now only bridging therapies to orthotopic liver transplantation, and much improvement is required to fulfill the main aim of cell transplantation, that of partially replacing the missing function without having to undergo liver transplantation [13]. Bridging therapy is very important in the case of pediatric liver diseases, especially because it helps in extending the lifespan of children until liver transplantation can be safely performed. More preclinical studies regarding the long-term engraftment and hepatocyte

repopulation are necessary, and more clinical data as well as controlled clinical experimentation are required not only with regard to dosage, application route and therapeutic mechanisms involved but also on the potential bidirectional role of the stem cells in carcinogenesis before firm conclusions can be drawn on the benefit of stem cells in acute or chronic liver diseases.

## Acknowledgements

Victor Navarro-Tableros for photograph of decellularized scaffold and Rinaldo Pellicano for critical reading of the manuscript.

Grants to F.A.- Progetti di ricerca di interesse nazionale (PRIN) 2010, Telethon 2014, Prometeo, Advanced Life Science in Italy (Alisei).

## Author Disclosure Statement

No competing financial interests exist.

## References

1. Duncan AW, C Dorrell and M Grompe. (2009). Stem cells and liver regeneration. *Gastroenterology* 137:466-81.
2. Tolosano E, S Fagoonee, N Morello, F Vinchi and V Fiorito. (2010). Heme scavenging and the other facets of hemopexin. *Antioxid Redox Signal* 12:305-20.
3. Kmiec Z. (2001). Cooperation of liver cells in health and disease. *Adv Anat Embryol Cell Biol* 161:III-XIII, 1-151.
4. Pellicano R, A Menard, M Rizzetto and F Megraud. (2008). Helicobacter species and liver diseases: association or causation? *Lancet Infect Dis* 8:254-60.
5. Adams DH and SG Hubscher. (2006). Systemic viral infections and collateral damage in the liver. *Am J Pathol* 168:1057-9.
6. Paschos KA, AW Majeed and NC Bird. (2014). Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance. *World J Gastroenterol* 20:3719-37.
7. Moreno R and M Berenguer. (2006). Post-liver transplantation medical complications. *Ann Hepatol* 5:77-85.
8. Fisher RA and SC Strom. (2006). Human hepatocyte transplantation: worldwide results. *Transplantation* 82:441-9.
9. Fitzpatrick E, RR Mitry and A Dhawan. (2009). Human hepatocyte transplantation: state of the art. *J Intern Med* 266:339-57.
10. Grossman M, JM Wilson and SE Raper. (1993). A novel approach for introducing hepatocytes into the portal circulation. *J Lab Clin Med* 121:472-8.
11. Grossman M, SE Raper and JM Wilson. (1992). Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity. *Hum Gene Ther* 3:501-10.
12. Jorns C, EC Ellis, G Nowak, B Fischler, A Nemeth, SC Strom and BG Ericzon. (2012). Hepatocyte transplantation for inherited metabolic diseases of the liver. *J Intern Med* 272:201-23.
13. Cantz T, AD Sharma and M Ott. (2015). Concise review: cell therapies for hereditary metabolic liver diseases-concepts, clinical results, and future developments. *Stem Cells* 33:1055-62.
14. Ezzat TM, DK Dhar, PN Newsome, M Malago and SW Olde Damink. (2011). Use of hepatocyte and stem cells for treatment of post-resectional liver failure: are we there yet? *Liver Int* 31:773-84.
15. Kidambi S, RS Yarmush, E Novik, P Chao, ML Yarmush and Y Nahmias. (2009). Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance. *Proc Natl Acad Sci U S A* 106:15714-9.

16. Fukuda J and K Nakazawa. (2011). Hepatocyte spheroid arrays inside microwells connected with microchannels. *Biomicrofluidics* 5:22205.
17. Levy G, D Bomze, S Heinz, SD Ramachandran, A Noerenberg, M Cohen, O Shibolet, E Sklan, J Braspenning and Y Nahmias. (2015). Long-term culture and expansion of primary human hepatocytes. *Nat Biotechnol* 33:1264-1271.
18. Navarro V, S Herrine, C Katopes, B Colombe and CV Spain. (2006). The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database. *Liver Transpl* 12:652-8.
19. Soltys KA, A Soto-Gutierrez, M Nagaya, KM Baskin, M Deutsch, R Ito, BL Shneider, R Squires, J Vockley, C Guha, J Roy-Chowdhury, SC Strom, JL Platt and IJ Fox. (2010). Barriers to the successful treatment of liver disease by hepatocyte transplantation. *J Hepatol* 53:769-74.
20. Hentze H, PL Soong, ST Wang, BW Phillips, TC Putti and NR Dunn. (2009). Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. *Stem Cell Res* 2:198-210.
21. Gordillo M, T Evans and V Gouon-Evans. (2015). Orchestrating liver development. *Development* 142:2094-108.
22. Miyajima A, M Tanaka and T Itoh. (2014). Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. *Cell Stem Cell* 14:561-74.
23. Austin TW and E Lagasse. (2003). Hepatic regeneration from hematopoietic stem cells. *Mech Dev* 120:131-5.
24. Mikkola HK and SH Orkin. (2006). The journey of developing hematopoietic stem cells. *Development* 133:3733-44.
25. Than NN and PN Newsome. (2014). Stem cells for liver regeneration. *QJM* 107:417-21.
26. Sakaida I, S Terai, N Yamamoto, K Aoyama, T Ishikawa, H Nishina and K Okita. (2004). Transplantation of bone marrow cells reduces CCl<sub>4</sub>-induced liver fibrosis in mice. *Hepatology* 40:1304-11.
27. Forbes SJ and PN Newsome. (2012). New horizons for stem cell therapy in liver disease. *J Hepatol* 56:496-9.
28. Trebol Lopez J, T Georgiev Hristov, M Garcia-Arranz and D Garcia-Olmo. (2011). Stem cell therapy for digestive tract diseases: current state and future perspectives. *Stem Cells Dev* 20:1113-29.
29. Furst G, J Schulte am Esch, LW Poll, SB Hosch, LB Fritz, M Klein, E Godehardt, A Krieg, B Wecker, V Stoldt, M Stockschlader, CF Eisenberger, U Modder and WT Knoefel. (2007). Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. *Radiology* 243:171-9.
30. Schmelzle M, C Duhme, W Junger, SD Salhanick, Y Chen, Y Wu, V Toxavidis, E Csizmadia, L Han, S Bian, G Furst, M Nowak, SJ Karp, WT Knoefel, J Schulte Esch and SC Robson. (2013). CD39 modulates hematopoietic stem cell recruitment and promotes liver regeneration in mice and humans after partial hepatectomy. *Ann Surg* 257:693-701.
31. Shi M, ZW Liu and FS Wang. (2011). Immunomodulatory properties and therapeutic application of mesenchymal stem cells. *Clin Exp Immunol* 164:1-8.
32. Prockop DJ, M Brenner, WE Fibbe, E Horwitz, K Le Blanc, DG Phinney, PJ Simmons, L Sensebe and A Keating. (2010). Defining the risks of mesenchymal stromal cell therapy. *Cytotherapy* 12:576-8.
33. Itaba N, Y Matsumi, K Okinaka, AA Ashla, Y Kono, M Osaki, M Morimoto, N Sugiyama, K Ohashi, T Okano and G Shiota. (2015). Human mesenchymal stem cell-engineered hepatic cell sheets accelerate liver regeneration in mice. *Sci Rep* 5:16169.
34. Khan AA, MV Shaik, N Parveen, A Rajendraprasad, MA Aleem, MA Habeeb, G Srinivas, TA Raj, SK Tiwari, K Kumaresan, J Venkateswarlu, G Pande and CM Habibullah. (2010). Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. *Cell Transplant* 19:409-18.
35. Banas A, T Teratani, Y Yamamoto, M Tokuhara, F Takeshita, G Quinn, H Okochi and T Ochiya. (2007). Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. *Hepatology* 46:219-28.

36. Zhang Z, H Lin, M Shi, R Xu, J Fu, J Lv, L Chen, S Lv, Y Li, S Yu, H Geng, L Jin, GK Lau and FS Wang. (2012). Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. *J Gastroenterol Hepatol* 27 Suppl 2:112-20.
37. Wang Y, X Yu, E Chen and L Li. (2016). Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases. *Stem Cell Res Ther* 7:71.
38. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8:315-7.
39. Gimble JM, AJ Katz and BA Bunnell. (2007). Adipose-derived stem cells for regenerative medicine. *Circ Res* 100:1249-60.
40. Tobita M, S Tajima and H Mizuno. (2015). Adipose tissue-derived mesenchymal stem cells and platelet-rich plasma: stem cell transplantation methods that enhance stemness. *Stem Cell Res Ther* 6:215.
41. Dai LJ, HY Li, LX Guan, G Ritchie and JX Zhou. (2009). The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. *Stem Cell Res* 2:16-25.
42. Hu C and L Li. (2015). In vitro culture of isolated primary hepatocytes and stem cell-derived hepatocyte-like cells for liver regeneration. *Protein Cell* 6:562-74.
43. Shiota G and N Itaba. (2016). Progress in stem cell-based therapy for liver disease. *Hepatol Res*.
44. Houlihan DD and PN Newsome. (2008). Critical review of clinical trials of bone marrow stem cells in liver disease. *Gastroenterology* 135:438-50.
45. Koh YG, SB Jo, OR Kwon, DS Suh, SW Lee, SH Park and YJ Choi. (2013). Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. *Arthroscopy* 29:748-55.
46. Berardis S, C Lombard, J Evraerts, A El Taghdouini, V Rosseels, P Sancho-Bru, JJ Lozano, L van Grunsven, E Sokal and M Najimi. (2014). Gene expression profiling and secretome analysis differentiate adult-derived human liver stem/progenitor cells and human hepatic stellate cells. *PLoS One* 9:e86137.
47. Wang L, Q Han, H Chen, K Wang, GL Shan, F Kong, YJ Yang, YZ Li, X Zhang, F Dong, Q Wang, D Xu, ZJ Hu, SH Wang, A Keating, YL Bi, FC Zhang and RC Zhao. (2014). Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. *Stem Cells Dev* 23:2482-9.
48. Porada CD, C Sanada, CJ Kuo, E Colletti, W Mandeville, J Hasenau, ED Zanjani, R Moot, C Doering, HT Spencer and G Almeida-Porada. (2011). Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. *Exp Hematol* 39:1124-1135 e4.
49. Russo FP, MR Alison, BW Bigger, E Amofah, A Florou, F Amin, G Bou-Gharios, R Jeffery, JP Iredale and SJ Forbes. (2006). The bone marrow functionally contributes to liver fibrosis. *Gastroenterology* 130:1807-21.
50. Takahashi K and S Yamanaka. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126:663-76.
51. Fagoonee S, RM Hobbs, L De Chiara, D Cantarella, RM Piro, E Tolosano, E Medico, P Provero, PP Pandolfi, L Silengo and F Altruda. (2010). Generation of functional hepatocytes from mouse germ line cell-derived pluripotent stem cells in vitro. *Stem Cells Dev* 19:1183-94.
52. Espejel S, GR Roll, KJ McLaughlin, AY Lee, JY Zhang, DJ Laird, K Okita, S Yamanaka and H Willenbring. (2010). Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. *J Clin Invest* 120:3120-6.
53. Ma X, Y Duan, B Tschudy-Seney, G Roll, IS Behbahan, TP Ahuja, V Tolstikov, C Wang, J McGee, S Khoobyari, JA Nolte, H Willenbring and MA Zern. (2013). Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. *Stem Cells Transl Med* 2:409-19.
54. Chen YF, CY Tseng, HW Wang, HC Kuo, VW Yang and OK Lee. (2012). Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. *Hepatology* 55:1193-203.

55. Hong SG, CE Dunbar and T Winkler. (2013). Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells. *Mol Ther* 21:272-81.
56. Lin SL and SY Ying. (2013). Mechanism and method for generating tumor-free iPS cells using intronic microRNA miR-302 induction. *Methods Mol Biol* 936:295-312.
57. Ilic D, L Devito, C Miere and S Codognotto. (2015). Human embryonic and induced pluripotent stem cells in clinical trials. *Br Med Bull* 116:19-27.
58. Fagoonee S, R Pellicano, L Silengo and F Altruda. (2011). Potential applications of germline cell-derived pluripotent stem cells in organ regeneration. *Organogenesis* 7:116-22.
59. Guan K, K Nayernia, LS Maier, S Wagner, R Dressel, JH Lee, J Nolte, F Wolf, M Li, W Engel and G Hasenfuss. (2006). Pluripotency of spermatogonial stem cells from adult mouse testis. *Nature* 440:1199-203.
60. Loya K, R Eggenschwiler, K Ko, M Sgodda, F Andre, M Bleidissel, HR Scholer and T Cantz. (2009). Hepatic differentiation of pluripotent stem cells. *Biol Chem* 390:1047-55.
61. Amendola M, MA Venneri, A Biffi, E Vigna and L Naldini. (2005). Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. *Nat Biotechnol* 23:108-16.
62. Streckfuss-Bomeke K, J Jende, IF Cheng, G Hasenfuss and K Guan. (2014). Efficient generation of hepatic cells from multipotent adult mouse germ-line stem cells using an OP9 co-culture system. *Cell Reprogram* 16:65-76.
63. Fagoonee S, ES Famulari, L Silengo, E Tolosano and F Altruda. (2015). Long Term Liver Engraftment of Functional Hepatocytes Obtained from Germline Cell-Derived Pluripotent Stem Cells. *PLoS One* 10:e0136762.
64. Zhang Z, Y Gong, Y Guo, Y Hai, H Yang, S Yang, Y Liu, M Ma, L Liu, Z Li, WQ Gao and Z He. (2013). Direct transdifferentiation of spermatogonial stem cells to morphological, phenotypic and functional hepatocyte-like cells via the ERK1/2 and Smad2/3 signaling pathways and the inactivation of cyclin A, cyclin B and cyclin E. *Cell Commun Signal* 11:67.
65. Chen Z, M Sun, Q Yuan, M Niu, C Yao, J Hou, H Wang, L Wen, Y Liu, Z Li and Z He. (2016). Generation of functional hepatocytes from human spermatogonial stem cells. *Oncotarget* 7:8879-95.
66. Alison MR, P Vig, F Russo, BW Bigger, E Amofah, M Themis and S Forbes. (2004). Hepatic stem cells: from inside and outside the liver? *Cell Prolif* 37:1-21.
67. Shupe TD, AC Piscaglia, SH Oh, A Gasbarrini and BE Petersen. (2009). Isolation and characterization of hepatic stem cells, or "oval cells," from rat livers. *Methods Mol Biol* 482:387-405.
68. Herrera MB, S Bruno, S Buttiglieri, C Tetta, S Gatti, MC Deregibus, B Bussolati and G Camussi. (2006). Isolation and characterization of a stem cell population from adult human liver. *Stem Cells* 24:2840-50.
69. Selden C, SA Chalmers, C Jones, R Standish, A Quaglia, N Rolando, AK Burroughs, K Rolles, A Dhillon and HJ Hodgson. (2003). Epithelial colonies cultured from human explanted liver in subacute hepatic failure exhibit hepatocyte, biliary epithelial, and stem cell phenotypic markers. *Stem Cells* 21:624-31.
70. Tan J, P Hytioglou, R Wiczorek, YN Park, SN Thung, B Arias and ND Theise. (2002). Immunohistochemical evidence for hepatic progenitor cells in liver diseases. *Liver* 22:365-73.
71. Huch M, H Gehart, R van Boxtel, K Hamer, F Blokzijl, MM Versteegen, E Ellis, M van Wenum, SA Fuchs, J de Lig, M van de Wetering, N Sasaki, SJ Boers, H Kemperman, J de Jonge, JN Ijzermans, EE Nieuwenhuis, R Hoekstra, S Strom, RR Vries, LJ van der Laan, E Cuppen and H Clevers. (2015). Long-term culture of genome-stable bipotent stem cells from adult human liver. *Cell* 160:299-312.
72. Grompe M. (2014). Liver stem cells, where art thou? *Cell Stem Cell* 15:257-8.
73. Dumble ML, EJ Croager, GC Yeoh and EA Quail. (2002). Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. *Carcinogenesis* 23:435-45.
74. Pritchard MT and LE Nagy. (2010). Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr-1-deficient mice. *Am J Pathol* 176:2743-52.



75. Herrera MB, V Fonsato, S Bruno, C Grange, N Gilbo, R Romagnoli, C Tetta and G Camussi. (2013). Human liver stem cells improve liver injury in a model of fulminant liver failure. *Hepatology* 57:311-9.
76. Sokal EM. (2014). Treating inborn errors of liver metabolism with stem cells: current clinical development. *J Inherit Metab Dis* 37:535-9.
77. Majumder S, JH Siamwala, S Srinivasan, S Sinha, SR Sridhara, G Soundararajan, HR Seerapu and S Chatterjee. (2011). Simulated microgravity promoted differentiation of bipotential murine oval liver stem cells by modulating BMP4/Notch1 signaling. *J Cell Biochem* 112:1898-908.
78. Blaber EA, H Finkelstein, N Dvorochkin, KY Sato, R Yousuf, BP Burns, RK Globus and EA Almeida. (2015). Microgravity Reduces the Differentiation and Regenerative Potential of Embryonic Stem Cells. *Stem Cells Dev* 24:2605-21.
79. Dianat N, C Steichen, L Vallier, A Weber and A Dubart-Kupperschmitt. (2013). Human pluripotent stem cells for modelling human liver diseases and cell therapy. *Curr Gene Ther* 13:120-32.
80. Navarro-Tableros V, MB Herrera Sanchez, F Figliolini, R Romagnoli, C Tetta and G Camussi. (2015). Recellularization of rat liver scaffolds by human liver stem cells. *Tissue Eng Part A* 21:1929-39.
81. Mazza G, K Rombouts, A Rennie Hall, L Urbani, T Vinh Luong, W Al-Akkad, L Longato, D Brown, P Maghsoudlou, AP Dhillon, B Fuller, B Davidson, K Moore, D Dhar, P De Coppi, M Malago and M Pinzani. (2015). Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. *Sci Rep* 5:13079.
82. Bortolussi G, L Zentilin, G Baj, P Giraudi, C Bellarosa, M Giacca, C Tiribelli and AF Muro. (2012). Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer. *FASEB J* 26:1052-63.
83. Kurtz A. (2008). Mesenchymal stem cell delivery routes and fate. *Int J Stem Cells* 1:1-7.
84. Nacif LS, AO Ferreira, DA Maria, MS Kubrusly, N Molan, E Chaib, LC D'Albuquerque and W Andraus. (2015). Which is the best route of administration for cell therapy in experimental model of small-for size syndrome in rats? *Acta Cir Bras* 30:100-6.
85. Gilchrist ES and JN Plevris. (2010). Bone marrow-derived stem cells in liver repair: 10 years down the line. *Liver Transpl* 16:118-29.
86. Nagamoto Y, K Takayama, K Ohashi, R Okamoto, F Sakurai, M Tachibana, K Kawabata and H Mizuguchi. (2016). Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure. *J Hepatol* 64:1068-75.
87. Tetta C, S Bruno, V Fonsato, MC Deregibus and G Camussi. (2011). The role of microvesicles in tissue repair. *Organogenesis* 7:105-15.
88. Herrera MB, V Fonsato, S Gatti, MC Deregibus, A Sordi, D Cantarella, R Calogero, B Bussolati, C Tetta and G Camussi. (2010). Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats. *J Cell Mol Med* 14:1605-18.
89. Collino F, MC Deregibus, S Bruno, L Sterpone, G Aghemo, L Viltono, C Tetta and G Camussi. (2010). Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. *PLoS One* 5:e11803.
90. Fonsato V, F Collino, MB Herrera, C Cavallari, MC Deregibus, B Cisterna, S Bruno, R Romagnoli, M Salizzoni, C Tetta and G Camussi. (2012). Human liver stem cell-derived microvesicles inhibit hepatoma growth in SCID mice by delivering antitumor microRNAs. *Stem Cells* 30:1985-98.
91. Mizrak A, MF Bolukbasi, GB Ozdener, GJ Brenner, S Madlener, EP Erkan, T Strobel, XO Breakefield and O Saydam. (2013). Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. *Mol Ther* 21:101-8.
92. Rani S, AE Ryan, MD Griffin and T Ritter. (2015). Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. *Mol Ther* 23:812-23.
93. Yang D, ZQ Wang, JQ Deng, JY Liao, X Wang, J Xie, MM Deng and MH Lu. (2015). Adipose-derived stem cells: A candidate for liver regeneration. *J Dig Dis* 16:489-98.
94. Oren R, Y Breitman, E Gur, A Traister, I Zvibel, E Brazovsky, DA Shafritz and Z Halpern. (2005). Whole fetal liver transplantation--a new approach to cell therapy. *Liver Transpl* 11:929-33.

95. Couto BG, RC Goldenberg, LM da Fonseca, J Thomas, B Gutfilen, CM Resende, F Azevedo, DR Mercante, AL Torres, HS Coelho, A Maiolino, AL Alves, JV Dias, MC Moreira, AL Sampaio, MA Sousa, TH Kasai-Brunswick, SA Souza, AC Campos-de-Carvalho and GF Rezende. (2011). Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study. *Liver Int* 31:391-400.
96. Garcia-Olmo D, D Herreros, I Pascual, JA Pascual, E Del-Valle, J Zorrilla, P De-La-Quintana, M Garcia-Arranz and M Pascual. (2009). Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. *Dis Colon Rectum* 52:79-86.
97. Guadalajara H, D Herreros, P De-La-Quintana, J Trebol, M Garcia-Arranz and D Garcia-Olmo. (2012). Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. *Int J Colorectal Dis* 27:595-600.
98. Fox IJ, JR Chowdhury, SS Kaufman, TC Goertzen, NR Chowdhury, PI Warkentin, K Dorko, BV Sauter and SC Strom. (1998). Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. *N Engl J Med* 338:1422-6.
99. Tolosa L, S Lopez, E Pareja, MT Donato, A Myara, TH Nguyen, JV Castell and MJ Gomez-Lechon. (2015). Human neonatal hepatocyte transplantation induces long-term rescue of unconjugated hyperbilirubinemia in the Gunn rat. *Liver Transpl* 21:801-11.
100. Carpentier A, A Tesfaye, V Chu, I Nimgaonkar, F Zhang, SB Lee, SS Thorgeirsson, SM Feinstone and TJ Liang. (2014). Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. *J Clin Invest* 124:4953-64.
101. Berardis S, P Dwisthi Sattwika, M Najimi and EM Sokal. (2015). Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects. *World J Gastroenterol* 21:742-58.
102. Alison MR, S Islam and S Lim. (2009). Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. *J Pathol* 217:282-98.
103. Zimmerlin L, TS Park, ET Zambidis, VS Donnerberg and AD Donnerberg. (2013). Mesenchymal stem cell secretome and regenerative therapy after cancer. *Biochimie* 95:2235-45.
104. O'Connor ML, D Xiang, S Shigdar, J Macdonald, Y Li, T Wang, C Pu, Z Wang, L Qiao and W Duan. (2014). Cancer stem cells: A contentious hypothesis now moving forward. *Cancer Lett* 344:180-7.
105. Roskams T. (2006). Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. *Oncogene* 25:3818-22.
106. Mishra L, T Banker, J Murray, S Byers, A Thenappan, AR He, K Shetty, L Johnson and EP Reddy. (2009). Liver stem cells and hepatocellular carcinoma. *Hepatology* 49:318-29.
107. Wu XZ and D Chen. (2006). Origin of hepatocellular carcinoma: role of stem cells. *J Gastroenterol Hepatol* 21:1093-8.
108. Fagoonee S, H Li, H Zhang, F Altruda and R Pellicano. (2014). Gastric cancer as a stem-cell disease: data and hypotheses. *Panminerva Med* 56:289-300.
109. Bakhuraysah MM, C Siatskas and S Petratos. (2016). Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality? *Stem Cell Res Ther* 7:12.
110. Jones CV and EA Copelan. (2009). Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. *Future Oncol* 5:559-68.
111. Gordon MY, N Levicar, M Pai, P Bachellier, I Dimarakis, F Al-Allaf, H M'Hamdi, T Thalji, JP Welsh, SB Marley, J Davies, F Dazzi, F Marelli-Berg, P Tait, R Playford, L Jiao, S Jensen, JP Nicholls, A Ayav, M Nohandani, F Farzaneh, J Gaken, R Dodge, M Alison, JF Apperley, R Lechler and NA Habib. (2006). Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. *Stem Cells* 24:1822-30.
112. Le Blanc K, C Gotherstrom, O Ringden, M Hassan, R McMahon, E Horwitz, G Anneren, O Axelsson, J Nunn, U Ewald, S Norden-Lindeberg, M Jansson, A Dalton, E Astrom and M Westgren. (2005). Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. *Transplantation* 79:1607-14.
113. Wakitani S, M Nawata, K Tensho, T Okabe, H Machida and H Ohgushi. (2007). Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. *J Tissue Eng Regen Med* 1:74-9.

114. Zeinaloo A, KS Zanjani, MM Bagheri, M Mohyeddin-Bonab, M Monajemzadeh and MH Arjmandnia. (2011). Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy. *Pediatr Transplant* 15:E183-6.
115. Kharaziha P, PM Hellstrom, B Noorinayer, F Farzaneh, K Aghajani, F Jafari, M Telkabadi, A Atashi, M Honardoost, MR Zali and M Soleimani. (2009). Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. *Eur J Gastroenterol Hepatol* 21:1199-205.
116. El-Ansary M, I Abdel-Aziz, S Mogawer, S Abdel-Hamid, O Hammam, S Teaema and M Wahdan. (2012). Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. *Stem Cell Rev* 8:972-81.
117. Amer ME, SZ El-Sayed, WA El-Kheir, H Gabr, AA Gomaa, N El-Noomani and M Hegazy. (2011). Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. *Eur J Gastroenterol Hepatol* 23:936-41.
118. Riordan NH, TE Ichim, WP Min, H Wang, F Solano, F Lara, M Alfaro, JP Rodriguez, RJ Harman, AN Patel, MP Murphy, RR Lee and B Minev. (2009). Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. *J Transl Med* 7:29.
119. Cho YB, WY Lee, KJ Park, M Kim, HW Yoo and CS Yu. (2013). Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. *Cell Transplant* 22:279-85.

STEM CELL TYPE	PRECLINICAL STUDIES	SOME OF CLINICAL STUDIES	REFERENCES
HSC(Hematopoietic stem cells)	Rodents, rabbit	Multiple sclerosis Myeloid Leukemia Liver cirrhosis	Bakhuraysah <i>et al.</i> 2016 [109] Jones <i>et al.</i> 2009 [110] Gordon <i>et al.</i> 2006 [111]
Bone marrow-derived MSCs	Rodents, rabbit, pig, porcine, monkey	Osteogenesis imperfecta Cartilage defects Myocardial infarction Liver cirrhosis Liver cirrhosis Liver cirrhosis Chronic hepatitis C Primary biliary cirrhosis Hepatic cirrhosis	Le Blanc <i>et al.</i> 2005 [112] Wakitani <i>et al.</i> 2007 [113] Zeinaloo <i>et al.</i> 2011 [114] Karaziha <i>et al.</i> 2009 [115] El-Ansary <i>et al.</i> 2011 [116] Zhang <i>et al.</i> 2011 [36] Amer ME <i>et al.</i> 2011 [117] Wang <i>et al.</i> 2014 [47] Dai <i>et al.</i> 2009 [41]
Adipose tissue-derived MSCs	Rodents, rabbit, pig, porcine, monkey	Multiple sclerosis Liver cirrhosis Crohn's fistula	Riordan <i>et al.</i> 2009 [118] Karaziha <i>et al.</i> 2009 [115] Cho <i>et al.</i> 2013 [119]
Human liver stem/rogenitor cells)	Rodents	Crigler-Najjar Syndrome type I Urea cycle disorders	Wang <i>et al.</i> 2016 [37] Herrera <i>et al.</i> 2013 [75] Herrera <i>et al.</i> 2006 [68] Sokal <i>et al.</i> 2016 [76]
Spermatogonial stem cells/ GPSCs (Germline cell-derived pluripotent stem cells)	Rodents	—	Fagoonee <i>et al.</i> 2015 [63] Chen <i>et al.</i> 2016 [65]

Table 1